BMP4
Reaktivität: Human
WB, IHC, IF
Wirt: Kaninchen
Monoclonal
unconjugated
Applikationshinweise
ELISA: 4-8 µg/mL, Inhibition: 0.4-0.6 µg/mL, WB: 0.25-0.5 µg/mL Optimal conditions should be determined by the investigator.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Lyophilized
Konzentration
Lot specific
Buffer
Lyophilized from PBS.
Handhabung
Avoid repeated freeze/thaw cycles. Dilute only prior to immediate use.
Lagerung
4 °C/-20 °C
Informationen zur Lagerung
Store at -20 °C until reconstitution. Following reconstitution product may be stored at 4 °C in the short term. For long term storage aliquot and freeze at -20 °C.
Calpe, Correia, Sancho-Serra, Krishnadath: "Comparison of newly developed anti-bone morphogenetic protein 4 llama-derived antibodies with commercially available BMP4 inhibitors." in: mAbs, Vol. 8, Issue 4, pp. 678-88, (2017) (PubMed).
Bone morphogenetic proteins (BMPs) constitute a subfamily within the TGF beta superfamily of structurally related signaling proteins. Members of this superfamily are widely distributed throughout the body and are involved in diverse physiological processes during both pre- and postnatal life. Like BMP-7, BMP-4 is involved in the development and maintenance of bone and cartilage. Reduced expression of BMP-4 is associated with a number of bone diseases, including the heritable disorder Fibrodysplasia Ossificans Progressiva. Synonyms: Monoclonal BMP4 antibody, Anti-BMP4 antibody, BMP-4 antibody, Bone Morphogenetic antibody, 4 antibody, BMP-2B antibody, DVR4 antibody.